Tag: marketing

Explore the Science Behind ProZenith’s Non-Stimulant Metabolic Support

In this 2025 report on the best bad credit loan providers with guaranteed approval and no credit check required, we examine how MoneyMutual stands out in a shrinking industry. As other platforms disappear or get flagged for compliance violations, MoneyMutual continues to connect borrowers with fast $500 loans, emergency cash advances, and secure same-day lending access—even for people with low or no credit scores.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Him Directly To Discuss Their Options

WINTER GARDEN, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Smith Profits™, in association with Junior Patriots, a 501c(3) nonprofit organization, announces that its founder, Robert J. Smith, MFA, The Father of Factual Storytelling’s latest release, INFLUENCE IN ACTION™ GAINS PROVEN RESULTS AND DRIVES SALES is an International #1 Best Seller.

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, inclusive (the “Class Period”), have until September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit charges Neogen and certain of Neogen’s top executives with violations of the Securities Exchange Act of 1934.

Session titled “Fresh Ideas to Attract Customers” will explore how behavioral economics and automation drive marketing performance

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –